Literature DB >> 3034455

Determination of creatine kinase isozymes in sera and tissues of patients with various lung carcinomas.

A Usui, K Fujita, M Imaizumi, T Abe, K Inoue, S Matumoto, K Kato.   

Abstract

Three creatine kinase isozymes (CK-BB, CK-MB and CK-MM) were estimated by immunoassay in tumor tissues and in sera of patients with various lung carcinomas. CK-BB was increased in small cell carcinoma, but not in other lung carcinomas. CK-MM and CK-MB were not increased in any types of carcinoma. Serum CK-BB was increased in all types of lung carcinoma examined, while serum CK-MM and CK-MB were within normal limits in all patients. Serum CK-BB of healthy adults was estimated as 0.32 +/- 0.14 (mean +/- SD) ng/ml, ranging from 0.11-0.68 ng/ml. If CK-BB values above 1.0 ng/ml were considered abnormal, elevation occurred in 28/40 (70%) of patients with small cell carcinoma, 25/67 (37%) with adenocarcinoma, 21/51 (41%) with squamous cell carcinoma, 4/11 (36%) with other carcinoma of the lung and 10/42 (24%) with lung tuberculosis. Since serum CK-BB with lung cancer changed in parallel with the clinical course, this isozyme may be a marker for monitoring the clinical course, especially in small cell carcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034455     DOI: 10.1016/0009-8981(87)90106-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas.

Authors:  J Joseph; A Cardesa; J Carreras
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Creatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambaréné, Gabon.

Authors:  Paulin N Essone; Bayode R Adegbite; Marien J M Mbadinga; Armel V Mbouna; Fabrice Lotola-Mougeni; Ayodele Alabi; Jean R Edoa; Bertrand Lell; Abraham S Alabi; Ayola A Adegnika; Michael Ramharter; Joel F D Siawaya; Martin P Grobusch; Peter G Kremsner; Selidji T Agnandji
Journal:  Infection       Date:  2022-02-08       Impact factor: 7.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.